Abstract 5530: PD-L1 expression in patients screened for phase 2 head and neck squamous cell carcinoma clinical studies (HAWK and CONDOR)

Sophie Wildsmith(AstraZeneca (United Kingdom)), Lillian L. Siu(University Health Network), Dan P. Zandberg(University of Pittsburgh Medical Center), Anita Midha(AstraZeneca (United Kingdom)), Jill Walker(AstraZeneca (United Kingdom)), Craig Barker(AstraZeneca (United Kingdom)), M. Ratcliffe(AstraZeneca (United Kingdom)), Marietta Scott(AstraZeneca (United Kingdom)), Marlon C. Rebelatto(AstraZeneca (Japan)), Jessica Whiteley(AstraZeneca (United Kingdom))
Cancer Research
July 1, 2018
10.1158/1538-7445.am2018-5530
Cited by 4

Related Papers

Dose Escalation Methods in Phase I Cancer Clinical Trials
|JNCI Journal of the National Cancer Institute|2009|856
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Oncology|2020|502
Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group
|Journal of Clinical Oncology|2005|448